Format

Send to

Choose Destination
Biochim Biophys Acta. 2010 Jan;1802(1):212-20. doi: 10.1016/j.bbadis.2009.10.007. Epub 2009 Oct 21.

Mitochondria: a therapeutic target in neurodegeneration.

Author information

1
Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.

Abstract

Mitochondrial dysfunction has long been associated with neurodegenerative disease. Therefore, mitochondrial protective agents represent a unique direction for the development of drug candidates that can modify the pathogenesis of neurodegeneration. This review discusses evidence showing that mitochondrial dysfunction has a central role in the pathogenesis of Alzheimer's, Parkinson's and Huntington's diseases and amyotrophic lateral sclerosis. We also debate the potential therapeutic efficacy of metabolic antioxidants, mitochondria-directed antioxidants and Szeto-Schiller (SS) peptides. Since these compounds preferentially target mitochondria, a major source of oxidative damage, they are promising therapeutic candidates for neurodegenerative diseases. Furthermore, we will briefly discuss the novel action of the antihistamine drug Dimebon on mitochondria.

PMID:
19853657
PMCID:
PMC2790540
DOI:
10.1016/j.bbadis.2009.10.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center